Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Molecular Assay for Aspergillosis Evaluated Under Clinical Conditions

By Labmedica International staff writers
Posted on 22 Nov 2011
A molecular test to detect the presence of invasive Aspergillus (IA) in critical care and hematology patients has been evaluated.

The polymerase chain reaction (PCR) assay was appraised to test the reliability and performance of the Myconostica assay compared with clinical diagnosis and conventional diagnostic tests, such as culture and blood tests.

A single-center prospective study was carried out at the Università Cattolica del Sacro Cuore (Rome, Italy) on a total of 158 bronchoalveolar lavage (BAL) fluid specimens that were consecutively collected from 68 hematology and 90 intensive care unit patients. There were 16 of 17 (94.1%) specimens from patients with proven/probable IA were that were positive with the commercial PCR MycAssay (Myconostica; Manchester, UK) and 15 of these 16 patients were also positive by an “in house” PCR assay. Of 141 specimens from patients without proven/probable IA, 139 (98.6%) were MycAssay negative. Fifteen of 16 (94.1%) positive patients were also positive for BAL galactomannan (GM) at an index cutoff of ≥1.0 (index range, 1.1 to 8.3), as were three patients without IA but with pulmonary fusariosis.

Interestingly, in seven of the PCR-positive BAL specimens that tested culture positive for Aspergillus species cycle-threshold values were earlier than those of specimens with a culture-negative result. In conclusion, the MycAssay Aspergillus as reported by Lab21, (Cambridge, UK) appears to be a sensitive and specific molecular test for the diagnosis of IA, and its performance is comparable to that of the GM assay. However, more large studies are necessary to establish its clinical utility in high-risk settings.

Aspergillus is an airborne fungus that can infect immunosuppressed patients, for example, those undergoing organ transplantation or treatment for hematological malignancies IA also poses a risk to hospitalized patients, such as those suffering with chronic obstructive pulmonary disease (COPD), liver cirrhosis and those taking corticosteroid treatment. There are estimated to be over 200,000 IA cases annually worldwide and over 10 million patients at risk. Mortality rates vary by patient group ranging from 30% to 85%.

Berwyn Clarke, PhD, chief scientific officer at Lab21 said: “The results of this evaluation confirm that our new CE-marked assay for the diagnosis of IA represents a first-in-class addition to fungal diagnostics enabling faster, more reliable and sensitive case detection. We are in the process of conducting additional studies to firmly establish its clinical utility in high-risk settings.” The study was published on October 19, 2011, in the Journal of Clinical Microbiology.

Related Links:

Università Cattolica del Sacro Cuore
Myconostica
Lab21




KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
Dubai Bio Expo-2015

Channels

Genetic Tests

view channel
Image: The final result of a DNA sequencing process, with each color representing one of the four base chemicals, adenine, guanine, cytosine and thymine, that comprise DNA (Photo courtesy of Gerald Barber).

Gene Sequencing Reference Standard Increases Accuracy for Medical Laboratories

To reduce the variability in genetic test results that has been observed across different clinical laboratories and pathology groups, a new standard DNA reference has been introduced, which will improve... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.